Patents Assigned to Xencor, Inc.
  • Heterodimeric antibodies that bind CD3 and CD38
    Patent number: 10526417
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 7, 2020
    Assignee: XENCOR, INC.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal
  • Targeting regulatory T cells with heterodimeric proteins
    Patent number: 10519242
    Abstract: The present invention provides methods and compositions comprising a heterodimeric antibody comprising a first monomer comprising a first variant heavy chain constant region and an anti-CD4 binding moiety. The heterodimeric antibody also comprises a second monomer comprising: a second variant heavy chain constant region and an anti-CD25 binding moiety. In some cases, the pIs of the first and second variant heavy chain constant regions are at least 0.5 logs apart.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 31, 2019
    Assignee: Xencor, Inc.
    Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachchi, John Desjarlais
  • IL15/IL15R? heterodimeric Fc-fusion proteins
    Patent number: 10501543
    Abstract: The present invention is directed to novel IL15/IL15R? heterodimeric Fc fusion proteins.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: December 10, 2019
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • Heterodimeric proteins
    Patent number: 10487155
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: November 26, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Heterodimeric proteins
    Patent number: 10472427
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: November 12, 2019
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Gregory Moore, Rumana Rashid, Matthew Bernett
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20190330342
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: July 9, 2019
    Publication date: October 31, 2019
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20190315861
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: May 21, 2019
    Publication date: October 17, 2019
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Trispecific antibodies
    Patent number: 10428155
    Abstract: The invention provides trispecific antibodies that co-engage CD3, CD8 and a tumor target antigen.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: October 1, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, John Desjarlais, Seung Chu, Sung-Hyung Lee
  • Fc variants with altered binding to FcRn
    Patent number: 10336818
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: July 2, 2019
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Heterodimeric antibodies that bind somatostatin receptor 2
    Patent number: 10316088
    Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2).
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: June 11, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Rumana Rashid, Sung-Hyung Lee, Paul Foster
  • Heterodimeric proteins
    Patent number: 10287364
    Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: May 14, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Rumana Rashid, John Desjarlais
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 10259887
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 16, 2019
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and PSMA
    Patent number: 10227410
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and PSMA.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: March 12, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, John Desjarlais, Seung Chu
  • Modulation of T cells with bispecific antibodies and FC fusions
    Patent number: 10227411
    Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: March 12, 2019
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Seung Chu, Dilki Wickramarachichi, John Desjarlais
  • Optimized Fc variants and methods for their generation
    Patent number: 10183999
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: January 22, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Optimized Fc variants and methods for their generation
    Patent number: 10184000
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 22, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • CTLA4-Ig immunoadhesins
    Patent number: 10155800
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: December 18, 2018
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Optimized antibody variable regions
    Patent number: 10131710
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: November 20, 2018
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Anti-glypican-3 antibody
    Patent number: 10118959
    Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 6, 2018
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Xencor, Inc.
    Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
  • Fc variants with increased affinity for FcyRIIc
    Patent number: 10113001
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 30, 2018
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes